1World Health Organization. Hepatitis B. World Health Organiza-tion Fact Sheet 204 ( Revised August 2004 ). Available at http://www. who. int/mediacentre/factsh eets/fs204/eii/.
4McMahon BJ,Alward WL,Hall DB,et al. Acute hepatitis B virus infection :relation to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis,1985 ,151 :599-603.
5Tassopoulos NC,Papa vangelou GJ,Sjogren MH,et al. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology, 1987 ,92 ; 1844-1850.
6Chang MH. Naturahistory of hepatitis B virus infection in children. J Gastroenterol Hepatol,2000 ,15( Suppl) :S16-19.
7Hoofnagle JH, Doo E,Liang TJ,et al. Management of hepatitis B : summary of a clinical research workshop. Hepatology, 2007,45 : 1056-1075.
9Shepherd J, Jones J,Takeda A, et al. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B : a systematic review and economic evaluation. Health Technol Assess, 2006, 10: 1-183.
10Sims KA, Woodland AM. Entecavir : a new nucleoside analog for the treatment of chronic hepatitis B infection. Pharmacotherapy,2006,26 : 1745-1757.
7Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
